Publication: 2604

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 35 (6) 591-597
Year:
2017
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
Yes
Book Volume:
6
Parents:
2533  
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U10CA032291, U10CA047577, U10CA077440, U10CA077651, U10CA077658, U10CA138561, U10CA180791, U10CA180833, U10CA180850, U10CA180857, U10CA180867, P30 CA008748, U10 CA180821, U10 CA180833, U10 CA180882  
Corr. Author:
 
Authors:
                           
Networks:
CA824, KS055, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC010, LAPS-NY016, LAPS-OH007   
Study
Alliance-A031203
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Rapid Communications, Chemotherapy, Chemotherapy, ORIGINAL REPORTS, Rapid Communication